ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 177 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,897,000 | +53.8% | 50,700 | +2.0% | 0.14% | +52.8% |
| Q1 2018 | $2,534,000 | -30.0% | 49,700 | -36.4% | 0.09% | -19.8% |
| Q4 2017 | $3,622,000 | -12.9% | 78,100 | 0.0% | 0.11% | -36.9% |
| Q3 2017 | $4,160,000 | -14.2% | 78,100 | 0.0% | 0.18% | +144.4% |
| Q2 2017 | $4,851,000 | -8.4% | 78,100 | 0.0% | 0.07% | -14.3% |
| Q1 2017 | $5,294,000 | +13.4% | 78,100 | +17.6% | 0.08% | +2.4% |
| Q4 2016 | $4,669,000 | -11.4% | 66,400 | -10.6% | 0.08% | -11.8% |
| Q3 2016 | $5,271,000 | +42.2% | 74,300 | -2.0% | 0.09% | +63.2% |
| Q2 2016 | $3,707,000 | +54.5% | 75,800 | +100.0% | 0.06% | +42.5% |
| Q1 2016 | $2,399,000 | -34.2% | 37,900 | +16.6% | 0.04% | -29.8% |
| Q4 2015 | $3,646,000 | +78.6% | 32,500 | +53.3% | 0.06% | +62.9% |
| Q3 2015 | $2,042,000 | – | 21,200 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |